Status:
UNKNOWN
Clinical, Virological, Serological and Immunological Characteristics During and Following COVID-19 Hospitalization
Lead Sponsor:
Nordsjaellands Hospital
Collaborating Sponsors:
Statens Serum Institut
Rigshospitalet, Denmark
Conditions:
COVID-19 Pneumonia
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Assessment of the association between the severity of COVID-19 and SARS-CoV-2 NAb titers levels for up to six months following primary infection using a live virus NAb assay. Description of SARS-CoV-2...
Detailed Description
The studys primary aim is to assess clinical factors, such as disease severity, associated with neutralizing antibody (NAb) production. Furthermore, the study aims to assess the length of SARS-CoV-2 i...
Eligibility Criteria
Inclusion
- positive SARS-CoV-2 specimen from upper or lower respiratory tracts (virological criteria)
- consolidations on the chest X-ray described by a radiologist, treating physician or a physician from the study group (radiological criteria)
- the presence of one or more of the following: fever (temperature ≥38.0°C), new-onset cough, pleuritic chest pain, dyspnea or altered breath sounds on auscultation (clinical criteria)
Exclusion
- cognitive impairment prohibiting giving informed consent to participation
- by December 14th, 2020, and onwards patients if the time since symptom onset was \> seven days at the time of inclusion
Key Trial Info
Start Date :
May 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05274373
Start Date
May 24 2020
End Date
October 1 2023
Last Update
March 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen University Hospital at North Zealand
Copenhagen, Denmark, 25482